UROV - Urovant Sciences: A New Competitor In The Market For Overactive Bladder
Urovant Sciences' (UROV) share price has been hit through the coronavirus in 2020 and has not been rising despite the company expecting approval for its main asset Vibegron on December 26, 2020. Furthermore, with sell-side consensus with potential sales peak over $600 M and an overseeable shareholder structure comprised of Sumitomo Dainippon Pharma and Perceptive Advisors ( ~ 80%), the perspective for Urovant should be clearly positive. However, there are some problems related to Vibegron, which we will address in our article.
Overactive bladder
Overactive bladder, also called OAB, is the name